Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.22 USD
+0.13 (11.93%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $1.23 +0.01 (0.82%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth F Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
Lexicon Pharmaceuticals, Inc.'s return on equity, or ROE, is -83.63% compared to the ROE of the Medical - Biomedical and Genetics industry of -67.20%. While this shows that LXRX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
LXRX 1.22 +0.13(11.93%)
Will LXRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LXRX
Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know
Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates
LXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
KURA Stock Rises More Than 15% This Past Week: Here's Why
Other News for LXRX
MACD Bearish Centerline Cross appears for LXRX after 0.91% move
Lexicon Pharmaceuticals: Promising Phase 2b Results for Pilavapadin Support Buy Rating
20 Day Moving Average Resistance appears for LXRX after 1.79% move
Lexicon Pharmaceuticals (LXRX) Highlights Promising Phase 2b Study Results
Lexicon announces presents data from Phase 2 PROGRESS study for pilavapadin